Media Library

Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy.
Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial.
Dianna Shafer talks about the testing protocol when examining patients’ bones and what they prescribe to ensure their patients’ bone health is being addressed.
Dianna Shafer talks about when testing shows metastasis, and how they use Xgeva when a patient is in this state.
Pam Skurkay, Dianna Shafer, and Angela Hunter discuss the rates of incidences of this issue as well as the benefits of using Xgeva, including a better quality of life for patients.
Pam Skurkay discusses the comparison rate of skeletal related events in bisphosphonates versus Xgeva.
Pam Skurkay, Dianna Shafer, and Angela Hunter talk about how technology and new medicines are not only helpful for patients, but assists researchers and providers in finding more information including locating clinical trials.
Page 2 of 4
Results 11 - 20 of 35